Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance

Inovio Pharmaceuticals IncTrade
YieldMax Nasdaq 100 0DTE Covered Call Strategy ETFTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.7. The key difference: YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

INOQDTY
Market Cap
$78.55M
Sector
HealthIncome / Options Overlay
52-Week High
$2.87$46.71
52-Week Low
$0.66$36.57
Enterprise Value
$49.56M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF

QDTY trades at $39.75, showing minimal daily movement with a -0.13% decline. The technical picture remains neutral overall with bearish moving averages, while the company demonstrates consistent dividend distributions through its weekly payout structure. Recent YieldMax ETF announcements highlight ongoing distribution activities through mid-2026.

The stock presents income-focused appeal through regular distributions, though fundamental metrics remain unavailable for comprehensive valuation assessment. Key considerations include reliance on ETF distribution strategies and market volatility exposure. The neutral technical stance suggests limited near-term directional momentum.

Returns comparison

Trailing returns across standard periods

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO

About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF

QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.

Read more on QDTY